Jump directly to main navigation Jump directly to content Jump to sub navigation

Institute of Novel and Emerging Infectious Diseases (INNT

Zoonotic Anticipation and Preparedness Initiative. Short title: IMI-ZAPI

INNT

Laufzeit: 03/2015 – 07/2021

Förderung: EU-Horizon Programm

The aim of the project is to devise strategies for rapid vaccine development in response to new and emerging infectious diseases. The project therefore developed platforms for rapid identification and production of viral domains that can be used as veterinary vaccines. They also serve as a starting point for the generation of efficient and protective antibodies to protect animals and the human population. Rift Valley fever virus (RVFV), Schmallenberg virus (SBV), and Middle East respiratory syndrome coronavirus (MERS-CoV) have been used as model viruses. Focusing on RVFV, INNT is involved in several work packages in cooperation with other project partners. Relevant virus domains were first identified by modern in silico analyses. Selected domains were subsequently produced in different expression systems on one hand as vaccine candidates and on the other hand as antigens for the production of virus neutralizing antibodies. As part of the efficacy testing of the vaccines obtained in this way, challenge experiments were carried out at INNT in mouse and sheep models with the best vaccine and antibody candidates.

Further information can be found on the project page:

https://www.imi.europa.eu/projects-results/project-factsheets/zapi

Involved INNT scientists:

Dr. Markus Keller
Dr. Martin Eiden
Prof. Dr. Martin H. Groschup

Dr. Benjamin Gutjahr (PostDoc)

Stall_web.jpg

Work in the high containment laboratories at the FLI (BSL-3, © FLI)

Project partner:

Finovatis, Lyon, Frankreich
http://www.finovatis.com/fr/

Harbour Antibodies, Rotterdam, Niederlande
http://harbourantibodies.com/

Artemis One Health Research, Utrecht, Niederlande
https://www.artemisonehealth.com/

Dyadic NDL, Wageningen, Niederlande
https://www.dyadic.com/dyadic-netherlands-to-develop-enzymes-for-eu-funded-research-consortium/

Aix-Marseille University, Marseille, Frankreich
https://www.univ-amu.fr/en

Stiftung Tierärztliche Hochschule Hannover, Deutschland
https://www.tiho-hannover.de/

Institut de Recerca / Tecnologia Agroalimentries (IRTA/ex-CReSA), Barcelona, Spanien
http://www.cresa.cat/cresa3/default.asp?mod=strmenu01&anio=2016&sub=noticia379&idioma=en

Agencia Estatal Consejo Superior de Investigaciones Cientificas (CSIC), Madrid, Spanien
https://www.csic.es/en

Viroclinics Bioscienes, Rotterdam, Niederlande
https://www.viroclinics.com/

Universitätsklinikum Bonn (UKB, Bonn, Deutschland
https://www.ukbonn.de/42256BC8002AF3E7/direct/home

International Alliance for Biological Standardization, Lyon, Frankreich
https://www.iabs.org/

Institut Pasteur, Paris, Frankreich
https://www.pasteur.fr/en

Leiden University Medical Center (LUMC), Leiden, Niederlande
https://www.universiteitleiden.nl/en/medicine-lumc

Utrecht University, Faculty of veterinary Medicine, Utrecht, Niederlande
https://www.uu.nl/en/organisation/faculty-of-veterinary-medicine

Central Veterinary Institute, Wageningen, Niederlande
https://www.wur.nl/en/Research-Results/Research-Institutes/Bioveterinary-Research.htm

Erasmus Medical Center, Rotterdam, Niederlande
https://www.erasmusmc.nl/en/research/departments/viroscience

Astra Zeneca / Medimmune, Södertälje, Schweden
https://www.astrazeneca.com/

Boehringer Ingelheim Animal Health, Ingelheim am Rhein, Deutschland
https://www.boehringer-ingelheim.de/tiergesundheit/uebersicht

Merial, Paris, Frankreich
https://www.boehringer-ingelheim.fr/sante-animale/notre-vision?merial=true